3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(2-(2-methoxyethoxy)ethyl)propanamide | 724722-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(2-(2-methoxyethoxy)ethyl)propanamide
• 英文别名: 3-(2,5-dioxopyrrol-1-yl)-N-[2-(2-methoxyethoxy)ethyl]propanamide
• CAS: 724722-89-8
• 化学式: C₁₂H₁₈N₂O₅
• 分子量: 270.28
• InChiKey: JCTGVOWJPZBVHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS PHOTO-PROTECTEURS ADHÉSIFS ET LEURS UTILISATIONS
  申请人：SKINOSIVE

  公开号：WO2021123116A1

  公开（公告）日：2021-06-24

  The present invention relates to a compound represented by the following formula (I): A[B-(C)v]w, wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

  本发明涉及一种由以下公式（I）表示的化合物：A[B-(C)v]w，其中A是光保护基团，B是连接基团，C是功能基团，v是从1到2000的整数，w是从1到6的整数。它还涉及包含该化合物的组合物，更具体地说，是化妆品或防晒霜组合物。还涉及在化妆品和治疗应用中使用这种化合物。该发明还涉及在药品和化妆品中减少光降解和/或光不稳定性的化合物的使用。该发明还涉及包含支撑物和该化合物粘附在该支撑物上的材料。
• PLATINUM-ACRIDINE COMPOUNDS AND METHODS OF TREATING CANCERS
  申请人：Wake Forest University

  公开号：US20210330679A1

  公开（公告）日：2021-10-28

  Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

  铂金-花菁和其类似物作为抗癌细胞毒剂。还提供了使用hMATE1（SLC47A1）作为生物标志物来识别可能对这些药物产生反应的肿瘤的方法，并通过表观遗传学使肿瘤组织对靶向该膜转运体的抗癌药物敏感化。
• Immune response modifier compositions and methods
  申请人：Stoermer Doris

  公开号：US10005772B2

  公开（公告）日：2018-06-26

  The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.

  本发明提供了一种免疫应答调节剂（IRM）组合物，它包括 IRM 分子和与 IRM 分子共价连接的第二活性分子，其中共价连接包括直接连接到 IRM 分子上的可变键。
• RNAi therapy for hepatitis B virus infection
  申请人：Arrowhead Pharmaceuticals, Inc.

  公开号：US10806750B2

  公开（公告）日：2020-10-20

  Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.

  描述了抑制乙型肝炎病毒基因表达的组合物和方法。描述了用于抑制乙型肝炎病毒基因表达的 RNA 干扰（RNAi）触发器和 RNAi 触发器共轭物。还描述了包含一种或多种 HBV RNAi 触发器（可选择与一种或多种附加治疗药物一起使用）的药物组合物。在体内将所述 HBV RNAi 触发器输送到受感染的肝脏可抑制 HBV 基因的表达并进行治疗。
• PEGYLATED INSULIN LISPRO COMPOUNDS
  申请人：Beals John Michael

  公开号：US20090312236A1

  公开（公告）日：2009-12-17

  The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.